Business · 19/10/1998Updated: 10/17/2026 · 1 min read
FDA Clears Way for Sutilains Ointment USP Approval
Summary
The Food and Drug Administration (FDA) has determined that sutilains ointment USP (Travase Ointment) was not withdrawn from sale due to safety or effectiveness concerns, paving the way for the approval of abbreviated new drug applications (ANDA's) for the product.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →